It was observed that pancreatic cancer cells with higher IL-17RB expression (HPAF-II, BxPC3, Capan-2, and CFPAC-1) were more resistant to gemcitabine treatment, and were pancreatic cancer cells with lower IL-17RB level (SU.86.86 and MIA-PaCa2) are more sensitive to gemcitabine treatment (Supplementary Fig. 4). Here, IL17RB is linked to pancreatic neoplasm.